MA54601A - Nouvelles protéines de liaison multi-spécifiques à base de pseudofab - Google Patents

Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Info

Publication number
MA54601A
MA54601A MA054601A MA54601A MA54601A MA 54601 A MA54601 A MA 54601A MA 054601 A MA054601 A MA 054601A MA 54601 A MA54601 A MA 54601A MA 54601 A MA54601 A MA 54601A
Authority
MA
Morocco
Prior art keywords
pseudofab
new
specific binding
binding proteins
based multi
Prior art date
Application number
MA054601A
Other languages
English (en)
Inventor
Christian Beil
Karl-Christian Engel
Gerhard Hessler
Soraya Hoelper
Christian Lange
Thomas Langer
Cendrine Lemoine
Wulf-Dirk Leuschner
Bruederle Sevim Oezguer
Ercole Rao
Nadja Spindler
Sandra Weil
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18306840.2A external-priority patent/EP3674319A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA54601A publication Critical patent/MA54601A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054601A 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab MA54601A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306840.2A EP3674319A1 (fr) 2018-12-24 2018-12-24 Protéines de liaison multispécifiques à base de pseudofab
EP19305813 2019-06-21

Publications (1)

Publication Number Publication Date
MA54601A true MA54601A (fr) 2022-03-30

Family

ID=69174547

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054601A MA54601A (fr) 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Country Status (16)

Country Link
US (2) US11739160B2 (fr)
EP (1) EP3902825A1 (fr)
JP (1) JP7734075B2 (fr)
KR (1) KR20220015369A (fr)
CN (1) CN114885609B (fr)
AU (1) AU2019416895A1 (fr)
BR (1) BR112021012337A2 (fr)
CA (1) CA3124770A1 (fr)
CO (1) CO2021009025A2 (fr)
IL (2) IL319262A (fr)
MA (1) MA54601A (fr)
MX (1) MX2021007677A (fr)
PH (1) PH12021500028A1 (fr)
SG (1) SG11202106393SA (fr)
TW (1) TW202041534A (fr)
WO (1) WO2020136564A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319262A (en) 2018-12-24 2025-04-01 Sanofi Sa Multispecific FAB pseudoproteins bind
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2024206669A2 (fr) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Anticorps pour cibler cd47 et b7h3 et leurs méthodes d'utilisation
WO2025262304A1 (fr) * 2024-06-20 2025-12-26 Sanofi Protéines de liaison comprenant un anticorps inhibiteur de point de contrôle ou un fragment de celui-ci, et des multimères de ligand de la superfamille des récepteurs du tnf à chaîne unique

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5732168A (en) 1995-10-31 1998-03-24 Hewlett Packard Company Thermal optical switches for light
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2410551A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Proteines de fusion heterodimeres
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2746330C (fr) 2008-12-23 2017-08-29 Genentech, Inc. Variantes d'immunoglobuline de proprietes de liaison vis-a-vis de la proteine a alterees
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CA2785414C (fr) 2009-12-25 2019-01-22 Tomoyuki Igawa Procede de modification de polypeptide pour purifier un multimere de polypeptide
ES2717883T3 (es) * 2010-03-25 2019-06-26 Ucb Biopharma Sprl Moléculas de DVD-LG estabilizadas con disulfuro
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
EP3517548A1 (fr) 2012-03-13 2019-07-31 NovImmune S.A. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
AU2013322710A1 (en) 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014106015A2 (fr) 2012-12-28 2014-07-03 Abbvie, Inc. Compositions protéiques à liaison multivalente
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015033223A2 (fr) 2013-09-03 2015-03-12 Novimmune S.A. Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
ES2936810T3 (es) * 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
US20170210818A1 (en) 2014-06-06 2017-07-27 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
EP3227332B1 (fr) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
ES3006358T3 (en) 2015-03-13 2025-03-18 Novimmune Sa Methods of purifying bispecific antibodies
US12595316B2 (en) 2015-07-09 2026-04-07 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
CA3020633A1 (fr) 2016-04-13 2017-10-19 Sanofi Proteines de liaison trispecifiques et/ou trivalentes
AU2018334886B2 (en) * 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
EP3674319A1 (fr) 2018-12-24 2020-07-01 Sanofi Protéines de liaison multispécifiques à base de pseudofab
IL319262A (en) 2018-12-24 2025-04-01 Sanofi Sa Multispecific FAB pseudoproteins bind
JP2023519699A (ja) * 2020-03-30 2023-05-12 サノフイ スプリットｃｈ２ドメイン
MX2023008966A (es) * 2021-02-07 2023-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpo biespecifico.

Also Published As

Publication number Publication date
WO2020136564A1 (fr) 2020-07-02
IL319262A (en) 2025-04-01
CN114885609A (zh) 2022-08-09
US11739160B2 (en) 2023-08-29
CO2021009025A2 (es) 2021-12-10
CA3124770A1 (fr) 2020-07-02
AU2019416895A1 (en) 2021-08-12
BR112021012337A2 (pt) 2021-09-14
PH12021500028A1 (en) 2022-05-02
IL284317A (en) 2021-08-31
IL284317B1 (en) 2025-06-01
US20200255540A1 (en) 2020-08-13
CN114885609B (zh) 2026-02-17
US20230391888A1 (en) 2023-12-07
JP2024504880A (ja) 2024-02-02
SG11202106393SA (en) 2021-07-29
TW202041534A (zh) 2020-11-16
AU2019416895A2 (en) 2021-09-09
IL284317B2 (en) 2025-10-01
EP3902825A1 (fr) 2021-11-03
JP7734075B2 (ja) 2025-09-04
MX2021007677A (es) 2021-12-10
KR20220015369A (ko) 2022-02-08

Similar Documents

Publication Publication Date Title
EP4225364A4 (fr) Protéines f hmpv stabilisées par préfusion
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
EP3655432A4 (fr) Protéines de liaison 1
EP3850007A4 (fr) Protéines bispécifiques modifiées
PT3649151T (pt) Proteínas de suporte
EP3717505A4 (fr) Protéines de liaison à l'adn modifiées
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3880814A4 (fr) Protéine de fusion
EP3307266A4 (fr) Nouvelles polythérapies à base de cannabinoïdes pour le myélome multiple (mm)
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
EP3917542A4 (fr) Protéines de liaison multispécifiques
EP3806645A4 (fr) Composition nutritionnelle à base de protéine de pois intacte
DK3784047T3 (da) Gærproteiner
IL290878A (en) Protein based cannabis compositions
MA54601A (fr) Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
DK3737402T5 (da) Modificeret protein
EP3514167A4 (fr) Peptide de liaison à la thrombospondine 1
EP4159872C0 (fr) Marquage de l'adn
EP3802565A4 (fr) Polypeptides
EP3612207C0 (fr) Polypeptides de coversine dépourvus de liaison c5
EP3974525A4 (fr) Protéine de substitution à base unique, et composition la comprenant
DK4034170T3 (da) Tgf-beta-polypeptider
DK3840767T3 (da) Peptider
EP4022337C0 (fr) Détermination de position